Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Ischemic Heart Disease (IHD) Drugs Market From 2025 To 2029?
In recent times, a consistent growth has been witnessed in the market size of drugs for Ischemic Heart Disease (IHD). The market, which is expected to escalate from $6.36 billion in 2024 to $6.65 billion in 2025, predicts an annual compound growth rate (CAGR) of 4.5%. Factors contributing to this growth during the historical period include an increased global incidence of ischemic heart disease, enhanced diagnostics and awareness, alterations in dietary habits and lifestyle, government-led cardiovascular health initiatives, partnerships for clinical trials, and insurance plus reimbursement policies.
In the coming years, the ischemic heart disease (IHD) drugs market is slated to experience stable expansion, inching towards a market value of $7.7 billion by 2029, signifying a compound annual growth rate (CAGR) of 3.7%. Factors such as the growing elderly population, individualized medication strategies, emphasis on preventative cardiovascular measures, worldwide health policies, and international research partnerships are believed to drive the growth during this forecast period. Additionally, the upcoming trends include a shift toward precision medication methodologies, a focus on groundbreaking anti-atherogenic agents, progress in lipid-reducing therapies, the incorporation of anti-inflammatory agents, and enhancement of antithrombotic and antiplatelet drugs.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp
What Are the Core Growth Drivers Propelling the Ischemic Heart Disease (IHD) Drugs Market Forward?
The rise in obesity and diabetes rates is projected to boost the expansion of the ischemic heart disease (IHD) drugs market. Diabetes, a chronic metabolic disorder that leads to elevated blood sugar levels, and obesity, a health condition characterized by extreme body fat accumulation that could harm health, are the key drivers. IHD medications are frequently employed in obese and diabetic patients to control cardiovascular risk factors such as hypertension and dyslipidemia, thereby reducing the risk of ischemic heart disease. For example, the World Obesity Federation, a UK-based organization leading global efforts to minimize, prevent, and manage obesity, reported in 2022, that by 2030, one billion individuals worldwide, including one in five women and one in seven men, will be obese. In another instance, the National Health Service, a UK government department, stated in June 2024, that in 2023, the NHS identified an additional 549,000 people in England at risk of developing type 2 diabetes, which increased the total number of people diagnosed with non-diabetic hyperglycemia or pre-diabetes, registered with a GP to 3,615,330. This is a substantial jump from 3,065,825 in 2022, reflecting a nearly 20% increase. Hence, the mounting occurrence of obesity and diabetes is stimulating the growth of the ischemic heart disease (IHD) drugs market.
What Segment Types Define the Ischemic Heart Disease (IHD) Drugs Market Structure?
The ischemic heart disease (ihd) drugs market covered in this report is segmented –
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Ischemic Heart Disease (IHD) Drugs Market?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Emerging Trends that Are Influencing theIschemic Heart Disease (IHD) Drugs Industry Evolution?
Major firms in the ischemic heart disease (IHD) drug market are shifting their efforts towards inventing innovative myosin inhibitors to get a leg up on their competition. Cardiac myosin inhibitors are medications that suppress the activity of myosin in heart muscle, thus reducing the force of contraction. These inhibitors are advantageous for health issues like hypertrophic cardiomyopathy (HCM), where excessive muscle thickening negatively affects heart performance. Bristol Myers Squibb, a pharmaceutical entity based in the United States, rolled out Camzyos (mavacamten) in April 2022 as an example. It is the initial cardiac myosin inhibitor authorized for adult treatment with symptomatic New York Heart Association class II-III obstructive HCM to enhance functional capacity and symptoms. The medication operates as an allosteric and reversible inhibitor that specifically targets cardiac myosin. It reduces hypercontractility, left ventricular hypertrophy, and betters cardiac filling pressures, which subsequently minimizes dynamic left ventricular outflow tract (LVOT) obstruction.
View the full report here:
What Is the Definition of the Ischemic Heart Disease (IHD) Drugs Market?
Ischemic heart disease (IHD) drugs are medications used to manage and treat a condition characterized by reduced blood flow to the heart muscle, often due to coronary artery narrowing. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13467
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model